Revolution Medicines (RVMD) Operating Expenses (2019 - 2026)

Revolution Medicines' Operating Expenses history runs 8 years deep, the most recent figure standing at $445.2 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 84.92% year-over-year to $445.2 million in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 75.68% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 71.48% from the prior year.
• Operating Expenses advanced to $445.2 million in Q1 2026 per RVMD's latest filing, from $361.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $445.2 million in Q1 2026 and bottomed at $65.5 million in Q1 2022.
• The 5-year median for Operating Expenses is $156.6 million (2024), against an average of $182.9 million.
• Across the five-year window, Operating Expenses soared 134.6% in 2023 and advanced 19.69% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $77.0 million in 2022, then surged by 134.6% to $180.7 million in 2023, then increased by 19.69% to $216.3 million in 2024, then jumped by 67.18% to $361.6 million in 2025, then grew by 23.12% to $445.2 million in 2026.
• Per Business Quant, the three latest RVMD Operating Expenses figures stand at $445.2 million (Q1 2026), $361.6 million (Q4 2025), and $315.3 million (Q3 2025).